sr141716 has been researched along with Neurogenic Inflammation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ankarali, S; Dagistan, Y; Kilinc, E; Torun, IE | 1 |
| Abe, T; Arisaka, O; Morimoto, H; Ohori, M; Yamada, Y; Yoshihara, S | 1 |
2 other study(ies) available for sr141716 and Neurogenic Inflammation
| Article | Year |
|---|---|
Receptor mechanisms mediating the anti-neuroinflammatory effects of endocannabinoid system modulation in a rat model of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Endocannabinoids; Male; Migraine Disorders; Neurogenic Inflammation; Nitroglycerin; Rats; Rimonabant; Substance P | 2022 |
Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways.
Topics: Amides; Animals; Arachidonic Acids; Bronchi; Bronchoconstriction; Calcium Channel Blockers; Camphanes; Cannabinoid Receptor Agonists; Capsaicin; Electric Stimulation; Endocannabinoids; Ethanolamines; Guinea Pigs; Male; Muscle Contraction; Muscle, Smooth; Nerve Fibers, Unmyelinated; Neurogenic Inflammation; Organ Culture Techniques; Palmitic Acids; Piperidines; Polyunsaturated Alkamides; Potassium Channel Blockers; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Substance P | 2005 |